Home›Iohexol

Iohexol

Also known as: Omnipaque

Radiographic Contrast AgentX-Ray Contrast Activity

Route: Intra-Articular, Intrathecal, Intravascular, Intravenous, Oral, Rectal

3 interactions on record⛔ Black Box Warning

Iohexol has 3 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Metformin, Radioactive Iodine, Radioactive Iodine (I-131 And I-123). Patients taking Iohexol should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 3

Major (3)

Iohexol + Metformin— Iodinated contrast agents increase risk of metformin-induced lactic acidosis, possibly by worsening renal function. Stop…
Iohexol + Radioactive Iodine— IOHEXOL may interfere with thyroid uptake of radioactive iodine (I-131 and I-123), decreasing therapeutic and diagnostic…
Iohexol + Radioactive Iodine (I-131 And I-123)— IOHEXOL may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid …

Iohexol + Metformin⚠️Major

Iodinated contrast agents increase risk of metformin-induced lactic acidosis, possibly by worsening renal function. Stop metformin at or prior to IOHEXOL administration in patients with eGFR 30-60 mL/min/1.73m², hepatic impairment, alcoholism, heart failure, or intra-arterial contrast use.

Iohexol + Radioactive Iodine⚠️Major

IOHEXOL may interfere with thyroid uptake of radioactive iodine (I-131 and I-123), decreasing therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post-IOHEXOL administration.

Iohexol + Radioactive Iodine (I-131 And I-123)⚠️Major

IOHEXOL may interfere with thyroid uptake of radioactive iodine and decrease therapeutic and diagnostic efficacy. Avoid thyroid therapy or testing for up to 6 weeks post-IOHEXOL administration.

⛔ FDA Black Box Warning

WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Warnings and Precautions (5.1) ]. WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 and 350 mg IODINE/mL Use only the iodine concentrations and presentations recommended for intrathecal procedures. Intrathecal administration of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema. ( 2.2 , 2.8 , 5.1 )

Contraindications

4 CONTRAINDICATIONS OMNIPAQUE for hysterosalpingography is contraindicated during pregnancy or suspected pregnancy, menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract including the external genitalia, and when reproductive tract neoplasia is known or suspected because of the risk of peritoneal spread of neoplasm. Hysterosalpingography during pregnancy (or suspected pregnancy), menstruation (or when menstruation is imminent), within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract, including the external genitalia, and when reproductive tract neoplasia is known or suspected. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary Hysterosalpingography is contraindicated in pregnant women due to the potential risk to the fetus from an intrauterine procedure [see Contraindications (4) ]. There are no data with iohexol use in pregnant women to inform any drug-associated risks. Iohexol crosses the placenta and reaches fetal tissues in small amounts ( see Data ) . In animal reproduction studies, no developmental toxicity occurred with intravenous iohexol administration to rats and rabbits at doses up to 0.4 (rat) and 0.5 (rabbit) times the maximum recommended human intravenous dose ( see Data ). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Literature reports show that intravenously administered iohexol crosses the placenta and is visualized in the digestive tract of exposed infants after birth. Animal Data Iohexol was neither embryotoxic nor teratogenic in either rats or rabbits at the following dose levels tested: 1.0, 2.0, 4.0 g iodine/kg in rats, administered intravenously to 3 groups of 25 dams once daily during days 6 through 15 of pregnancy; 0.3, 1.0, 2.5 g iodine/kg in rabbits, administered intravenously to 3 groups of 18 rabbits dosed once a day during days 6 through 18 of pregnancy.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.